Trajenta may reduce stroke damage
December 4, 2012Research and Development, Sales and Marketing Boehringer, EMA, Trajenta, diabetes, linagliptin
Boehringer Ingelheim’s diabetes drug Trajenta could one day be used to minimise the effects of brain damage following stroke. Scientists …
Excipient certification project moves forward
December 4, 2012Manufacturing and Production DEG, EXCiPACT, GDP, GMP
The EXCiPACT certification scheme for pharmaceutical excipients has taken a step closer to fruition with agreements now in place with …
R&D costs rise ten-fold
December 4, 2012Research and Development, Sales and Marketing OHE, R&D, research and development
Research by the Office of Health Economics (OHE) think tank shows that the cost of pharma R&D has risen ten-fold …
NHS ‘entering treacherous waters’
December 3, 2012Sales and Marketing Ham, NHS, coalition, king's fund, reforms
A leading think tank has marked the coalition government’s health policy with what amounts to a C+ in its mid-term …
J&J’s Alex Gorsky to be chairman and chief executive
December 3, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Johnson & Johnson has has elected its chief executive Alex Gorsky to be its chairman of the Board of directors. …
Pharmacos ink green manufacturing pact with EU academics
December 3, 2012Manufacturing and Production Bayer, EU, Pharmacos, Sanofi
A group of top pharma multinationals have set up a public-private partnership dedicated to the development of manufacturing sustainable pharmaceuticals …
Janssen eases HIV patent burden
December 3, 2012Sales and Marketing AIDS, Janssen, Prezista, darunavir
In a move which should appeal to public health campaigners, Janssen has declared that it will not enforce patents for …
Help CCGs help you, pharma told
November 30, 2012Medical Communications, Sales and Marketing CCGs, JSNA, NHS, pharma
Pharma companies have a big opportunity to take advantage of the changes in the structure of the NHS, according to …
Ranbaxy suspends atorvastatin manufacturing after recall
November 30, 2012Manufacturing and Production FDA, Ranbaxy, atorvastatin, recall
Ranbaxy Laboratories has called a halt to manufacturing its generic atorvastatin product until it can get to the bottom of …
New chief executive for Cipla
November 30, 2012Manufacturing and Production, Research and Development, Sales and Marketing Cipla, Subhanu Saxena
Indian pharma firm Cipla has announced the appointment of Novartis’ Subhanu Saxena as its chief executive. Saxena joins Cipla in …
NICE: ‘lot of work’ to do on VBP
November 30, 2012Medical Communications, Sales and Marketing Boysen, NHS, NICE, QALY, VBP
NICE is still working out what its role with the new NHS Commissioning Board will be, with other key issues …
Novartis R&D warning
November 29, 2012Research and Development, Sales and Marketing NHS, Novartis. R&D, trials
Novartis has hit out at what it sees as the high cost of UK clinical trials, warning that business will …
Eylea approval for wet AMD
November 29, 2012Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD
Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …
Genzyme appoints new GM for UK and Ireland
November 29, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brendan Martin, Genzyme
Genzyme has announced the appointment of Brendan Martin as general manager for UK and Ireland. Martin will be responsible for …
Survey: pharma losing $564 billion each year
November 28, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cap Gemini, Health Prize, pharma
Pharma companies are losing $564 billion each year – more than half the industry’s $956 billion revenue worldwide last year …
Another indication for Humira
November 28, 2012Sales and Marketing Abbott, Crohn's, EU, Humira
Abbott’s Humira has received its ninth indication in Europe with approval to treat youngsters suffering from the inflammatory bowel disease …
RSA welcomes new starter
November 28, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Huberts, rsa
Life Sciences Executive Search and Interim Management specialists RSA, has announced that Michael Huberts has joined the UK business as …
TranslateMedia listed in the Deloitte UK Fast 50 for the third year running
November 27, 2012Medical Communications
International translation and transcreation agency, TranslateMedia has been listed in the Deloitte UK Fast 50 for the third consecutive year, …
EMA’s five points on data release
November 27, 2012Medical Communications, Research and Development, Sales and Marketing EFPIA, EMA, Rasi, transparency
The European Medicines Agency has highlighted five areas that need to be ironed out before it begins publishing clinical trial …
‘Adopt NICE decisions’ committee told
November 27, 2012Sales and Marketing ABPI, Dorrell, NHS, NICE, Whitehead
ABPI chief executive Stephen Whitehead has again urged the NHS to adopt and use the drugs which NICE approves, and …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
